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ABSTRACT 
Novel drug delivery systems are now a day is creating a new interest in development of drug deliveries. The transdermal route of 
drug delivery has gained great interest of pharmaceutical research, as it circumvents number of problems associated with oral route 
of drug administration. Transferosomes are capable of transdermal delivery of low as well as high molecular weight drugs. This 
offers several potential advantages over conventional routes like avoidance of first pass metabolism, predictable and extended 
duration of activity, minimizing undesirable side effects, utility of short half life drugs, improving physiological and 
pharmacological response and have been applied to increases the efficiency of the material transfer across the intact skin, by the use 
of penetration enhancers and non-ionic surfactant vesicles. It is suitable for controlled and targeted drug delivery and it can 
accommodate drug molecules with wide range of solubility. Due to its high deformability it gives better penetration of intact 
vesicles. Transferosome possess an infrastructure consisting of hydrophobic and hydrophilic moieties together and as a result can 
accommodate drug molecules with wide range of solubility. They are biocompatible and biodegradable as they are made from 
natural phospholipids and have high entrapment efficiency. In this review, we have focused on transferosome with discussions on 
novel drug delivery systems for targeted delivery of therapeutics and important issues and challenges for future clinical applications. 
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Transfersome is a term registered as a trademark by the 
German company IDEA AG, and used by it to refer to 
its proprietary drug delivery technology. The name 
means “carrying body”, and is derived from the Latin 
word 'transferre', meaning “to carry across”, and the 
Greek word “soma”, for a “body”. A transfersome 
carrier is an artificial vesicle designed to be like a cell 
vesicle or a cell engaged in exocytosis, and thus suitable 
for controlled and, potentially targeted, drug delivery. 
Transferosomes are promising nanocarriers for non 
invasive transdermal delivery. Transferosomes are ultra 
deformable vesicles possessing an aqueous core 
surrounded by the complex lipid bilayer. 
Interdependency of local composition and shape of the 
bilayer makes the vesicle both self-regulating and self-
optimizing 
1
. Transferosomes are capable of transdermal 
delivery of low as well as high molecular weight drugs 
2
. 
Transferosomes are specially optimized, ultra flexible 
lipid supra molecular aggregates, which are able to 
penetrate the mammalian skin intact and then act as a 
drug carrier for non-invasive targeted drug delivery and 
sustained release of therapeutic agents 
3
. Transferosomes 
are colloidal carriers which are easily accumulated into 
the leaky synovial tissue which leads to peripheral 
targeting. Transferosomes also act as depot resulting in 
controlled drug delivery system. Better drug delivery by 
transferosomes is due to the driving force provided by 
the osmotic gradient between outer and inner layer of 
stratum corneum 
4
, thus, they can pass through the intact 
skin spontaneously under the influence of the naturally 
occurring in vivo transcutaneous hydration gradient. Due 
to their deformability, transferosomes are good 
candidates for the non-invasive delivery of small, 
medium, and large sized drugs. The transfersomes 
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components that sustain strong membrane deformation 
preferentially accumulate, while the less adaptable 
molecules are diluted at sites of great stress. This 
dramatically lowers the energetic cost of membrane 
deformation and permits the resulting, highly flexible 
particles, first to enter and then to pass through the pores 
rapidly and efficiently. This behavior is not limited to 
one type of pore and has been observed in natural 
barriers such as in intact skin 
5, 6
. Transferosomes are 
self adaptable and optimized mixed lipid aggregate. 
Transferosomes are artificial vesicles, being several 
orders of magnitude more deformable than standard 
liposomes. These are more elastic than standard 
liposomes. Transferosomes have been widely used as a 
novel carrier for effective transdermal drug delivery. 
MECHANISM OF ACTION 
Transferosomes overcome the skin penetration difficulty 
by squeezing themselves along the intracellular sealing 
lipids of stratum corneum (Figure 1). 
  
 
Figure 1: Schematic diagram describing interaction of the transferosome with skin tissue 
 
At present, the mechanism of enhancing the delivery of 
active substances in and across the skin is not very well 
known. Two mechanisms of action have been proposed 
7, 8
. Transferosomes act as drug vectors, remaining intact 
after entering the skin. Transferosomes act as 
penetration enhancers, disrupting the highly organized 
intercellular lipids from stratum corneum, and therefore 
facilitating the drug molecules penetration in and across 
the stratum corneum. The recent studies propose that the 
penetration and permeation of the vesicles across the 
skin are due to the combination of the two mechanisms. 
Depending on the nature of the active substance 
(lipophilic or hydrophilic) and the composition of the 
transferosomes, one of the two mechanisms prevails. 
After having penetrated through the outermost skin 
layers, transferosomes reach the deeper skin layer, the 
dermis. From this latter skin region they are normally 
washed out, via the lymph, into the blood circulation 
and through the latter throughout the body, if applied 
under suitable conditions. Transferosomes can thus 
reach all such body tissues that are accessible to the 
subcutaneously injected liposomes. The kinetics of 
action of an epicutaneously applied agent depends on 
the velocity of carrier penetration as well as on the speed 
of drug (re) distribution and the action after this passage. 
The most important single factors in this process are:  
• Carrier in-flow  
• Carrier accumulation at the targets site  
• Carrier elimination  
The onset of penetration-driving force depends on the 
volume of the suspension medium that must evaporate 
from the skin surface before the sufficiently strong 
trans-cutaneous chemical potential chemical potential or 
water activity gradient is established. Using less solvent 
is favourable in this respect. The rate of carrier passage 
across the skin is chiefly determined by the activation 
energy for the carrier deformation. 
COMPOSITION OF TRANSFEROSOMES 
Transfersomes are ultradeformable vesicle possessing an 
aqueous core surrounded by the complex lipid bilayer. 
Transferosomes possess an infrastructure consisting of 
hydrophobic and hydrophilic moieties together and as a 
result can accommodate drug molecules with wide range 
of solubility 
9
. Transferosomes can deform and pass 
through narrow constriction (from 5 to 10 times less 
than their own diameter) without measurable loss. The 
transfersome is composed of two main aggregates 
namely. Firstly, an amphipathic ingredient 
(phosphatidylcholine), in which the aqueous solvents 
self-assembles into lipid bilayer that closes into a simple 
lipid vesicle.  Secondly, a bilayer softening component 
(such as a biocompatible surfactant oramphiphile drug) 
that increases lipid bilayer flexibility and permeability. 
Transferosomes vesicles are composed of phospholipids 
as the main ingredient (soya phosphatidylcholine, egg 
phosphatidylcholine, dipalmityl phosphatidylcholine, 
etc), 10- 25% surfactants for providing flexibility 
(sodium cholate, tween 80, span-80), 3-10% alcohol as a 
solvent (ethanol, methanol) and hydrating medium 
consisting of saline phosphate buffer (pH 6.5-7). 
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They differ from liposomes because of the presence of 
so-called edge-activators, and comprise phospholipids 
as the main ingredient with 10-25% surfactant (e.g. 
sodium cholate) and 3-10% ethanol. The surfactants are 
the “edge activators”, which confer ultradeformability 
on the transferosomes. The elasticity of the vesicle is 
correlated with the quantity and the structure of the 
incorporated surfactant. In comparison with liposomes, 
it has been claimed that transferosomes are able to 
deliver their “payload” deeper into the skin. 
METHODS OF PREPARATION OF 
TRANSFERSOMES  
Transfersome vesicles are prepared in a similar manner 
as liposomes that includes sonicating, extrusion, low 
shear rates mixing (multilamellar liposomes), or high 
high-shear homogenisation unilamellar liposomes) of 
the crude vesicle suspension, except that no separation 
of the vesicle-associated and free drug is required. The 
preparation of transfersomes involves various process 
variables such as lecithin, surfactant ratio, effect of 
various solvents, effect of various surfactants and 
hydration medium. All the methods of preparation of 
transfersomes are comprised of two steps. First, a thin 
film is prepared hydrated and then brought to the desired 
size by sonication; and secondly, sonicated vesicles are 
homogenized by extrusion through a polycarbonate 
membrane (Figure 2). The mixture of vesicles forming 
ingredients, that is phospholipids and surfactant were 
dissolved in volatile organic solvent (chloroform 
methanol), organic solvent evaporated above the lipid 
transition temperature (50
 º
C for dipalmitoyl 
phosphatidyl choline) using rotary evaporator. Final 
traces of solvent were removed under vacuum for 
overnight. The deposited lipid films were hydrated with 
buffer (pH 6.5) by rotation at 60 rpm min-1 fir 1 hr at 
the corresponding temperature. The resulting vesicles 
were swollen for 2 hr at room temperature. To prepare 
small vesicles, resulting LMVs were sonicated at room 
temperature or 50
 º
C for 30 min. using a B-12 FTZ bath 
sonicator or probe sonicated at 40C for 30 min (titanium 
micro tip, Heat Systems W 380). The sonicated vesicles 
were homogenized by manual extrusion 10 times 






Figure 2: Method of preparation of transferosomes 
 
CHARACTERIZATION 
The mechanical properties and transport ability of a 
vesicle can be studied by measuring stress- or 
deformation-dependent vesicle bilayer elasticity and 
permeability changes. In a single experiment the 
objective may be reached by determining the pressure 
dependent area density of the transfersome suspension 
flux through a nano-porous filter, with pores at least 
50% smaller than the average vesicle size. Analysis of 
experimental penetrability vs. driving pressure curves 
can yield the characteristic bilayer elasticity and 
permeability values, based on theoretical description of 
material flow as an activated transport process. 
Visualization of transferosomes can be performed using 
transmission electron microscopy (TEM) and by 
scanning electron microscopy (SEM). Particle size and 
size distribution can be determined by dynamic light 
scattering (DLS) and photon correlation spectroscopy 
(PCS). The drug entrapment efficiency of 
transferosomes can be measured by the 
ultracentrifugation technique. Vesicle stability can be 
determined by assessing the size and structure of the 
vesicles over time and drug content can be quantified by 
HPLC or other spectrophotometric methods. In vitro 




APPLICATION OF TRANSFERSOMES  
They are used as a carrier for protein and peptides like 
insulin, bovine serum albumin, vaccines, etc. Because of 
their good penetration power and flexibility, 
transferosomes formulations are used for effective 
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delivery of non-steroidal antiinflammatory agents like 
ibuprofen and diclofenac. 
Insulin can be deliverd by encapsulating it into 
transferosomes. Insulin is generally administered by 
subcutaneous route that is inconvenient. Encapsulation 
of insulin into transferosomes (transfersulin) overcomes 
these entire problems. After transfersulin application on 
the intact skin, the first sign of systemic hypoglycemia 
are observed after 90 to 180 min, depending on the 
specific carrier composition 
12
. Transferosomes have 
been also used for the delivery of corticosteroids. 
Transferosomes improves the site specificity and overall 
drug safety of corticosteroid delivery into skin by 
optimizing the epicutaneously administered drug dose. 
Transferosomes based corticosteroids are biologically 
active at dose several times lower than the currently 
used formulation for the treatment of skin diseases 
13
. 
Transfersomes have been widely used as a carrier for the 
transport of proteins and peptides. Proteins and peptide 
are large biogenic molecules which are very difficult to 
transport into the body, when given orally they are 
completely degraded in the GI tract. These are the 
reasons why these peptides and proteins still have to be 
introduced into the body through injections. Various 
approaches have been developed to improve these 
situations. The bioavaibility obtained from 
transferosomes is somewhat similar to that resulting 
from subcutaneous injection of the same protein 
suspension. The transferosomal preparations of this 
protein also induced strong immune response after the 
repeated epicutaneous application, for example the 
adjuvant immunogenic serum albumin in 
transferosomes, after several dermal challenges is as 




Transferosomes have also been used as a carrier for 
interferons, for example leukocytic derived interferone-
α (INF-α) is a naturally occurring protein having 
antiviral, antiproliferive and some immunomodulatory 
effects. Transferosomes as drug delivery systems have 
the potential for providing controlled release of the 
administered drug and increasing the stability of labile 
drugs. Hafer et al studied the formulation of interleukin-
2 and interferone-α containing transferosmes for 
potential transdermal application .they reported delivery 
of IL-2 and INF- α trapped by transferosomes in 
sufficient concentration for immunotherapy 
16
. Anti 
cancer drugs like methotrexate were tried for 
transdermal delivery using transfersome technology. 
The results were favorable. This provided a new 
approach for treatment especially of skin cancer 
17, 18
. 
Application of anesthetics in the suspension of highly 
deformable vesicles, transferosomes, induces a topical 
anesthesia, under appropriate conditions, with less than 
10 min. Maximum resulting pain insensitivity is nearly 
as strong (80%) as that of a comparable subcutaneous 
bolus injection, but the effect of transferosomal 
anesthetics last longer [17]. NSAIDS are associated with 
number of GI side effects. These can be overcome by 
transdermal delivery using ultra-deformable vesicles. 
Studies have been carried out on diclofenac and 
ketoprofen. Ketoprofen in a transfersome formulation 
gained marketing approval by the Swiss regulatory 
agency (SwissMedic) in 2007; the product is expected to 
be marketed under the trademark diractin. Further 
therapeutic products based on the transfersome 
technology, according to IDEA AG, are in clinical 
development 
19
. Transferosomes have also used for the 
delivery of corticosteroids. Transferosomes improves 
the site specificity and overall drug safety of 
corticosteroid delivery into skin by optimizing the 
epicutaneously administered drug dose. Transferosomes 
beased cortiosteroids are biologically active at dose 
several times lower than the currently usd formulation 
for the treatment of skin diseases 
20
. Transfersomes have 
also been reported to improve the therapeutic efficacy of 
cyclosporine, and the site specificity and safety of 
corticosteroids. Transfersomes can penetrate stratum 
corneum and supply the nutrients locally to maintain its 
functions resulting maintenance of skin in this 
connection the transfersomes of capsaicin has been 
prepared by Xiao-Ying et al. which shows the better 
topical absorption in comparison to pure capsaicin 
21
. 
Herbal drugs can also be incorporated into 
transferosomes as they can penetrate stratum corneum 
supply nutrients locally to maintain its functioning. 
curcumin, capsaicin showed topical administration 
through transferosomal formulations. 
LIMITATIONS OF TRANSFEROSOMES  
Transferosomes are chemically unstable because of their 
predisposition to oxidative degradation. Purity of natural 
phospholipids is another criteria militating against 
adoption of Transferosomes as drug delivery vehicles. 
Transferosomes formulations are expensive 
3, 17, 22
. 
SCOPE OF TRANSFERSOMES 
Transfersome technology is best suited for noninvasive 
delivery of therapeutic molecules across open biological 
barriers. The transfersome vesicles can transport across 
the skin, for example, molecules that are too big to 
diffuse through the barrier. Examples include systemic 
delivery of therapeutically meaningful amounts of 
macromolecules, such as insulin or interferon, across 
intact mammalian skin. Other applications include the 
transport of small molecule drugs which have certain 
physicochemical properties which would otherwise 
prevent them from diffusing across the barrier. Another 
attraction of the transfersome technology is the carriers 
ability to target peripheral, subcutaneous tissue. This 
ability relies on minimization of the carrier associated 
drug clearance through cutaneous blood vessels plexus: 
the non-fenestrated blood capillary walls in the skin 
together with the tight junctions between endothelial 
cells preclude vesicles getting directly into blood, thus 
maximizing local drug retention and propensity to reach 
the peripheral tissue targets [
23, 24
. Scope of 
transfersomes is mainly intended for topical application 
although other routes may be considered for further 
investigations. Drug should be selected in such a way 
that it fits in the criteria of topical delivery. It should 
have ideal limits for aqueous solubility, lipophilicity, 
molecular size, melting point and pH of the aqueous 
saturated solution. Further in future by combining 
various other strategies, vesicular system will find the 
central place in novel drug delivery, particularly in 
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diseased cell sorting, diagnostics, gene and genetic 
materials, safe, targeted and effective in vivo delivery. 
CONCLUSION 
Transfersomes are the most promising transdermal drug 
carrier is the recently developed and patented 
Transfersome® which penetrates the skin barrier along 
the transcutaneous moisture gradient. This leads the 
carriers through the “virtual “pores between the cells in 
the organ without affecting its biological and general 
barrier properties. Transfersome carriers can create a 
highly concentrated drug depot in the systemic 
circulation. Transfersome carriers loaded with various 
agents of different molecular size and lipophilicity 
(lidocaine, tetracaine, cyclosporine, diclofenac, 
tamoxifen, etc.) have been shown to cross the skin 
barrier. In addition, polypeptides such as calcitonin, 
insulin, α- and γ- interferon, and, Cu – Zn super oxide 
dismutase, serum albumin, and dextrose have been 
successfully delivered across the skin with transfersome 
carriers. The future of controlled drug delivery is 
expected to grow phenomenonally and biomedical 
application of transfersomes is expected to increase and 
requires greater efforts towards investigating the non-
bilayer phases and exploring the mechanism of action. 
 
REFERENCES 
1. Cevc G, Grbauer D, Schatzlein A, Blume G. Ultraflexible 
vesicles, transferosomes, have an extremely low pore 
penetration resistance ant transport therapeutic amounts of 
insulin across the intact mammalian skin. Biochem Biophys 
Act 1998; 201-215. 
2. El-Maghraby GM, Williams AC. Vesicular systems for 
delivering conventional small organic molecules and larger 
macromolecules to and through human skin. Expert Opin 
Drug Deliv 2009; 149-163.  
3. Walve JR, Bakliwal SR, Rane BR, Pawar SP. 
Transferosomes: A surrogated carrier for transdermal drug 
delivery system. Int J App Bio Pharm Tech. 2011; 2 (1):201-
214. 
4. Kumar A, Pathak K, Bali V. Ultra-adaptable nanovesicular 
systems: a carrier for systemic delivery of therapeutic agents. 
Piroxicam Discovery Today 2012; 17(21- 22):1233-41 
5. Bain KR., Hadgkraft AJ, James WJ, and Water KA: 
Prediction of percutaneous penetration STS Publishing, 
Cardiff 1993; 3b:226-234. 
6. Cevc G, Blume G, Sehatzlein A, Gebauer D and Paul A: The 
skin- a pathway for systemic treatment with patches and 
lipid-based agent carriers Advance Drug Delivery Reviews 
1996; 18:349- 378 
7. Jain S., Jain P. Transferosomes: A novel vesicular carrier for 
enhanced transdermal delivery: development, 
characterization and performance evaluation, Drug Dev. Ind. 
Pharm. 2003; 29:1013-1026 
8. Paul A., Cevc G., Bachhawat B.K. Transdermal 
immunization with an integral membrane component, gap 
junction protein, by means of ultradeformable drug carriers, 
transferosomes, Vaccine. 1998; 16 (2-3):188-195. 
9. Jain NK. Advances in Controlled and Novel Drug Delivery. 
CBS Publishers and Distributers First edition. New Delhi. 
2001; 426-451. 
10. Fry DW, White JC and Goldman ID: Rapid separation of low 
molecular weight solutes from liposomes without dilution, 
Journal of Analytical Biochemistry 1978; 90:809-815. 
11. Touitou E., Godin B., Dayan N., Weiss C. Intracellular 
Delivery Mediated By An Ethosomal Carrier. Biomaterials. 
2001; 22:3053-3059. 
12. Gregor C, Dieter G, Juliane S, Andreas S, Gabriele B, 
“Ultra-flexible vesicles, Transfersomes, have an extremely 
low pore penetration resistance and transport therapeutic 
amounts of insulin across the intact mammalian skin”, 
Biophysica Acta, 1998, 1368:201-215. 
13. Cevc G, “Isothermal lipid phase”, Transitions Chemistry and 
Physics of Lipids, 1991, 57:293- 299. 
14. Maghraby EI, Williams GM, Barry BW, “Skin delivery of 
oestradiol from lipid vesicles: importance of liposome 
structure”, Int. J. Pharma, 2000, 204 (1-2):159-69.  
15. Trotta M, Peira E, Carlotti ME, Gallarate M, “Deformable 
liposomes for dermal administration of methotrexate”, Int. J. 
Pharma, 2004, 270:119. 
16. Hafer C, Goble R, Deering P, Lehmer A, Breut J, 
“Formulation of interleukin-2 and interferon-alpha 
containing ultra-deformable carriers for potential transdermal 
application”, Anticancer Res., 1999, 19 (2c), 1505-7. 
17. Modi CD, Bharadia PD, “Transfersomes: New Dominants 
for Transdermal Drug Delivery”, Am. J. PharmTech Res., 
2012, 2 (3):71-91. 
18. Benson HA, “Transfersomes for transdermal drug delivery”, 
Expert Opin. Drug Deliv., 2006, 3 (6):727-37. 
19. Dubey V, Mishra D, Asthana A, Jain NK, “Transdermal 
delivery of a pineal hormone: melatonin via elastic 
liposomes”, Biomaterials, 2006, 27 (18):3491-6.  
20. Cevc G, Blume G., Schatzlein A: Transfersomes-mediated 
transepidermal delivery improves the regiospecificity and 
biological activity of corticosteroids in vivo. Journal of 
Controlled Release 1997; 45:211- 226. 
21. Wang XR, Gao SQ, Niu XQ, Li LJ, Ying XY, Hu ZJ, Gao 
JQ. Capsaicin-loaded nanolipoidal carriers for topical 
application: design, characterization, and in vitro/ in vivo 
evaluation. International Journal of Nanomedicine 2017; 
12:3881–3898. 
22. Kombath RV, Minumula SK, Sockalingam A, Subadhra S, 
Parre S, Reddy TR, David B, “Critical issues related to 
transfersomes – novel Vesicular system”, Acta Sci. Pol., 
Technol. Aliment., 2012, 11 (1), 67-82. 
23. Cho YW and Flynn M. Oral delivery of Insulin Wletterx, 
Lancet, 1989; 23-30: 1518–1519.  
24. Wang PY. Implantable Reservoir for Supplemental Insulin 
Delivery on Demand by External Compression, Biomaterials, 
1989; 10: 197–201. 
 
 
 
 
 
 
